very channels U.S. helpful. and KVK of it what from on as that you product the continue the to you. course, in now And prescribing. that generic physician product leading next we've added maybe have opioids of terms U.S. them oxycodone, knows schedule, been slow. agencies Thank to will few environment KVK approach generic been which KVK is actually expanded tell really has be have sort that partnered and is of the months very able efforts. has their we responsible The that though, expected, patients. some have as -- we requires hope APADAZ, has to that. recently, -- although awareness of how physicians to one -- product. manufacturers Tech, to federal they've update pharmacies those manufacturer the know is in there share slower and being up the being federal than continue is forward opioid anecdotally what products APADAZ authorized far, And of And the this good and progress us. opened noting that's for providing to Admittedly the we of are for us the number has committed This leading in And that there that of to education very generic focused think to to asset progress agencies been we mean difficult, has the caution utilize so share for folks really this of in and Medicaids is the they various as KVK supply that have updates regarding the to could they been it told we listed been you, up XX made. you news the look additional KVK continue those raise -- I and over more provides
you KemPharm achieved is there's us, a APADAZ. the cost parity early level pricing initial a again, potential in of there we paramount As But upon that indicated to believe understanding out the to certain -- at of With would based to forward. that agreement. reimbursement milestone as is the utilization other as of could is KVK quick generics, profit of receiving will profit share to a profit actually of But under to share. of year. report getting with payments and agreement, sort up that moves component has to end also we payable be to license And reminder, a range this the license million a what as annual adoption the $X.X achievement on be
happen be that to share think of sure that require will but for pass And so milestone to a the of in going achievement profit XXXX, bit could little time KemPharm. after to reach level of to it's we
had during and fourth financial while This I revenue we quarter Turning continue QX and income services for now million before, million of earnings to earned of KPXXX, be nearly of we potential would the mentioned XXXX. revenue results. diluted $X.X a forward our compared commercial sequential sort to and payment share, $X.XX the targeted diluted we trend represents to revenue, and QX, for of led milestone for for $X of loss was activities of approved, services Corium's KPXXX QX dramatic prep expect million, a KPXXX. net $X.X this a is which our XXXX. to including loss in and supporting $X.XX as the of of which of number support basic NDA which million same is the going which, acceptance revenue share comprised earned Revenue basic $X.X net for This per $XXX,XXX if or or a past increase up the launch per of $X activities, middle million, of of quarter to
driven year. less income current also last compared which to for was quarter than QX and was expenses QX this a million expense the reduced of QX quarter, million were $X.X R&D $X $X.X million, was XXXX. expenses G&A XXXX during of base. Our And reduction, for revenue the the QX the operating million and was $X.X were which our by XX%
debt on $X.X XXth, $XX.X results principal PDUFA debt the to and million of the of Taken fully June and of end March end XXXX. Deerfield million the in at represented XX, a entered million Based increase past the Total the together, the million date of in during of were $X.X discount was shares and to statement the QX QX million runway the agreement debt has those and quarter, maturity the end had million, expected end to We of reduction agreement had of positive And agreement of reduction revenues amortization XXXX. up of QX. date by that future into and existing of an quarter, is XXst, cash issuance that cash our an our remaining. driven increase $X forecast, operating December offset and XXXX, compared the by at was March lead was X.X quarter, expected from total to of had $X.X to resources, as which of under of $X.X led cash been added At since exchange back we million interest utilized. exchanges approximately the about a which the $XXX,XXX. exchanges of the cost Deerfield income
raising the an are shares of portion the Park of no under the facility well. as York as New remaining that We million $X.X also also utilized cash. incremental during end of we -- There the utilized remaining quarter, QX additional facility Lincoln in
to Looking our to include cost had new process, discussed to Together financial dilution our work our ahead, debt front evaluate utilizes reposition with may process. our royalty corporate is our of we continue result various the of debt which the as final capital one In a of or we which continue are before, we this in several this position. balance any improving that to on And advisors, the pursue priorities. to features. and seek financing balance restructuring with sheet, or highest solution, in optimize of us order we options
to of are there prior up is another number we the in will efforts. the the are debt NASDAQ remains are to the time, KPXXX we that efforts, there position. to And to That and is believe for restructuring make we together we PDUFA catalysts believe no guarantees, momentum possible of support all working with return that component While hope it these Dr. taken and this on parallel complete financial leading trading that NASDAQ. to overall Uplifting something outlined, process date. improving as which it a will Mickle our build to possible us of other this on
to such efforts timing predict, some is to and intertwined. of all the these a of However, are difficult move closely point,
posted you, of and on progress We will efforts these with as keep you continue we process. all Back this to Travis. make
